ZTS Insider Trading

Insider Ownership Percentage: 0.16%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $451,783.99

Zoetis Insider Trading History Chart

This chart shows the insider buying and selling history at Zoetis by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$312ksoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$5M$0$5MTotal Insider BuyingTotal Insider Selling

Zoetis Share Price & Price History

Current Price: $163.03
Price Change: Price Decrease of -1.987 (-1.20%)
As of 03/28/2025 04:59 PM ET

This chart shows the closing price history over time for ZTS up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMar$163.03Closing price on 03/28/25:

SEC Filings (Institutional Ownership Changes) for Zoetis (NYSE:ZTS)

92.80% of Zoetis stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at ZTS by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$5.12Bbought$4.16BsoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$50B$0$50BTotal InflowsTotal Outflows
Zoetis logo
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.
Read More on Zoetis

Today's Range

Now: $163.03
Low: $162.82
High: $165.40

50 Day Range

MA: $166.40
Low: $156.43
High: $175.65

52 Week Range

Now: $163.03
Low: $144.80
High: $200.33

Volume

1,550,283 shs

Average Volume

2,595,079 shs

Market Capitalization

$73.00 billion

P/E Ratio

29.80

Dividend Yield

1.23%

Beta

0.94

Who are the company insiders with the largest holdings of Zoetis?

Zoetis' top insider shareholders include:
  1. Kristin C Peck (CEO)
  2. Heidi C Chen (EVP)
  3. Roxanne Lagano (EVP)
  4. Willie M Reed (Director)
  5. Robert J Polzer (EVP)
Learn More about top insider investors at Zoetis.

Who are the major institutional investors of Zoetis?

Zoetis' top institutional investors include:
  1. Vanguard Group Inc. — 9.17%
  2. State Farm Mutual Automobile Insurance Co. — 3.55%
  3. Alliancebernstein L.P. — 2.62%
  4. Bank of America Corp DE — 2.55%
  5. Geode Capital Management LLC — 2.35%
  6. Polen Capital Management LLC — 1.66%
Learn More about top institutional investors of Zoetis stock.

Which institutional investors are selling Zoetis stock?

In the last quarter, ZTS stock was sold by these institutional investors:
  1. Alliancebernstein L.P.
  2. FMR LLC
  3. Bank of America Corp DE
  4. Price T Rowe Associates Inc. MD
  5. William Blair Investment Management LLC
  6. Legal & General Group Plc
  7. International Assets Investment Management LLC
  8. Nuveen Asset Management LLC
During the previous year, company insiders that have sold Zoetis company stock include:
  1. Kristin C Peck (CEO)
  2. Heidi C Chen (EVP)
Learn More investors selling Zoetis stock.

Which institutional investors are buying Zoetis stock?

Within the last quarter, ZTS stock was purchased by institutional investors including:
  1. Norges Bank
  2. Wellington Management Group LLP
  3. Raymond James Financial Inc.
  4. Polen Capital Management LLC
  5. Capital Research Global Investors
  6. Amundi
  7. Northern Trust Corp
  8. Assenagon Asset Management S.A.